NeurogesX starts NGX-4010 Phase III

NeurogesX (San Carlos, Calif.) started a Phase III trial of its NGX-4010 trans-capsaicin dermal patch to treat postherpetic neuralgia (PHN). The primary endpoint of the U.S. double-blind trial is chan...